Glenmark Life Sciences inks pact with Japanese innovator pharmaceutical company

19 Jan 2024 Evaluate

Glenmark Life Sciences (GLS) has signed a Master Supply Agreement (MSA) with a Japanese innovator pharmaceutical company with global presence in Europe, United States and Asia. Under the aegis of the Master Supply Agreement, Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator.

The company will leverage its expertise in API manufacturing to support the global pharmaceutical innovator's initiative in the field of urinary anti-spasmodic therapeutics. As part of this collaboration, product portfolios of various affiliates of the global innovator may also be added in the future. The API for the finished formulation will be supplied to all major regulated markets such as United States, Europe and Japan. The estimated commercial value of this project is expected to be around $5 million.

Glenmark Life Sciences is in the business of making high-quality drugs by unlocking the possibilities of science.

Alivus Life Sciences Share Price

1034.35 4.05 (0.39%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...